|Articles|November 30, 2011

Dawn Holcombe Addresses the Continuing Challenges of Defining Evidence and Value in Oncology

Dawn Holcombe, President of DGH Consulting and Executive Director of the Connecticut Oncology Association, discusses how the increasing demand for data and defining evidence and value are so complex that collaboration between payers and providers is critical.

She also addresses her concern for the viability of the oncology market given the uncertainties of additional changes the federal government may make—especially in an election year—and how such changes could negatively impact the delivery of cancer care.


Related to this article

CAR T-cell therapy | Image: AdobeStock
In the years since the first approval for CAR T-cell therapy, major managed care plans have adopted mechanisms to include these treatments. But many employer-sponsored plans may not be required to cover them, and such treatments are "lasered out."